Agenus To Present Data On Botensilimab And AGEN1721 At SITC 2024; Novel Candidates Show Promise In Turning Cold And Refractory Tumors Into Responsive Targets
Agenus To Present Data On Botensilimab And AGEN1721 At SITC 2024; Novel Candidates Show Promise In Turning Cold And Refractory Tumors Into Responsive Targets
Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets
新型候選藥物展示出將冷漠和難治性腫瘤轉變爲可響應靶點的潛力
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D., Vice President of Research at Agenus.
艾吉納斯公司（"艾吉納斯"）（納斯達克：AGEN），是一家致力於開發新型免疫藥物治療各種癌症的領軍企業，今天宣佈了其兩個有前景的候選免疫治療藥物博特尼利單抗和AGEN1721的最新數據，將在德克薩斯州休斯頓舉行的海豐國際免疫療法協會2024年年會上展示。這些數據展示了在治療免疫耐藥腫瘤方面潛在的突破，將由艾吉納斯公司研究副總裁達恩·錢德博士（Dhan Chand, Ph.D.）進行介紹。
譯文內容由第三人軟體翻譯。
